Researchers at AAAAI Annual Meeting Show Eating Peanut in Early Years Reduces the Risk of Peanut Allergy, Even with Later Avoidance

Share Article

New England Journal of Medicine Peanut Study Makes Debut at AAAAI Annual Meeting

News Image
"LEAP-On clearly demonstrates that the majority of infants did in fact remain protected [from peanut allergies] and that the protection was long-lasting,” Gideon Lack, MD

Researchers from Kings College in London are reporting that infants who have been introduced to peanuts early in life are less likely to develop peanut allergies, even if they stop eating peanut around the age of five.

Published today in the New England Journal of Medicine, the Persistence of Oral Tolerance to Peanut (LEAP-On) study continued the work of the LEAP study. Results were presented at the AAAAI Annual Meeting in Los Angeles.

“The aim of our study was to find out whether infants who had consumed peanut in the LEAP study would remain protected against peanut allergy after they stopped eating peanut for 12 months. LEAP-On clearly demonstrates that the majority of infants did in fact remain protected and that the protection was long-lasting,” lead author Gideon Lack, MD, explained.

In the follow-up study, participants were instructed to to avoid peanuts for 12 months. The primary outcome was the percentage of participants with peanut allergy at the end of the 12-month period, when the participants were 72 months of age. Therefore, 550 participants from LEAP (out of a total of 628) were enrolled and asked to avoid peanuts for 12 months after completion of the LEAP study. Patients then participated in oral peanut challenges, food allergy questionnaires, skin prick tests (SPT) and blood tests (peanut-specific immune markers IgE and IgG4).

A total of 445 participants successfully avoided consuming significant amount of peanuts for the LEAP-On protocol. 90.4% (255/282) of peanut-consumers avoided peanuts and 69.3% (190/274) of peanut-avoiders continued to avoid peanuts.

The study found that at age 6, there was no statistically significant increase in allergy after 12 months of avoidance, in those who had previously consumed peanut during the LEAP trial (3.6% (10/274) at 60 months versus 4.8% (13/270) at 72 months). The study also found that peanut allergy continued to be significantly more prevalent in those who had avoided eating peanuts in the original LEAP study, than those who consumed (18.6% vs 4.8%).

“We concluded that in infants at high-risk for allergy in whom peanut was introduced in the first year of life, and continued until age 5, a 12-month period of peanut avoidance was not associated with a significant increase in peanut allergy. Overall, the study saw a 74% relative reduction in the prevalence of peanut allergy in those who consumed peanut compared to those who avoided,” Lack said.

It should be noted that the LEAP study design did not measure the minimum frequency or amount of peanut consumption that is required in early childhood to prevent an allergic response to peanut. Researchers are also calling for additional studies to establish whether the effects of early-life peanut consumption followed by continued consumption of peanut over many years maintains this protection against allergy.

“These findings are important because they demonstrate the potential for people to become tolerant to peanut, and not just desensitized,” said James R. Baker, Jr., MD, CEO and chief medical officer of FARE. “We are pleased to see that the results of the LEAP study have begun to make an impact through the updates to NIAID’s clinical guidance for physicians, which will address the role of early consumption in prevention of peanut allergy, and we believe that the findings from LEAP-On provide additional evidence that will be helpful in further informing advice for new parents from their healthcare providers.”

For more information on food allergies or the AAAAI Annual Meeting, visit the AAAAI website. Data sets for these analyses are accessible through TrialShare, a public website managed by the Immune Tolerance Network.

The AAAAI represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 6,800 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.


Editor's notes:

·This study was presented during the 2016 Annual Meeting of the American Academy of Allergy, Asthma & Immunology, March 4-7 in Los Angeles. However, it does not necessarily reflect the policies or the opinions of the AAAAI.

·A link to all abstracts/papers presented at the 2016 Annual Meeting is available at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Melissa Graham, Media & Member Communications Manager
Visit website